Hohl Benjamin
SEC CIK 1882764 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | CFO | 44.0K | — | $4.51M | 81 | 2023-12-22 | 2026-09-17 |
Most active insiders at ELVN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 10% | — | $51.68M |
| 2 | Derynck Mika K | Dir | — | $9.56M |
| 3 | Collins Helen Louise | Chief MEDICAL Off | — | $5.39M |
| 4 | Lyssikatos Joseph P | CSO | — | $4.88M |
| 5 | Patel Anish | COO | — | $1.74M |
| 6 | Hohl Benjamin | CFO | — | $1.60M |
| 7 | Kunkel Lori Anne | Dir | — | $850.3K |
| 8 | Kintz Samuel | Pres AND CEO, Dir | — | $613.6K |
| 9 | Heyman Richard A. | Dir | — | $413.4K |
Transactions 81
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-21 17:23 | 2026-09-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $14.85 | +3,982 | 44.0K | +10% | +$59.1K |
| DMT | 2026-09-21 17:23 | 2026-09-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $50.35 | -6,018 | 38.0K | -14% | -$303.0K |
| MT | 2026-08-19 16:17 | 2026-08-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale | $58.58 | -6,018 | 40.0K | -13% | -$352.6K |
| DT | 2026-07-21 17:24 | 2026-07-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +1,072 | 52.1K | +2% | +$2,659 |
| DMT | 2026-07-21 17:24 | 2026-07-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $52.64 | -6,018 | 46.1K | -12% | -$316.8K |
| DT | 2026-06-22 17:13 | 2026-06-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +6,018 | 57.0K | +12% | +$14.9K |
| DMT | 2026-06-22 17:13 | 2026-06-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $43.80 | -6,018 | 51.0K | -11% | -$263.6K |
| 2026-03-10 | 2026-03-06 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale | $29.58 | -10.0K | 51.0K | -16% | -$295.8K | |
| D | 2026-02-17 | 2026-02-12 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | A - Grant | $0.00 | +25.0K | 61.0K | +69% | $0 |
| D | 2025-12-23 | 2025-12-22 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +13.0K | 36.0K | +57% | +$32.2K |
| D | 2025-10-01 | 2025-09-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $20.40 | -3,250 | 23.0K | -12% | -$66.3K |
| D | 2025-10-01 | 2025-09-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 26.2K | +14% | +$8,060 |
| D | 2025-08-29 | 2025-08-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $20.63 | -3,250 | 23.0K | -12% | -$67.0K |
| D | 2025-08-29 | 2025-08-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 26.2K | +14% | +$8,060 |
| D | 2025-07-30 | 2025-07-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 26.2K | +14% | +$8,060 |
| DM | 2025-07-30 | 2025-07-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $20.47 | -3,250 | 23.1K | -12% | -$66.5K |
| D | 2025-07-14 | 2025-07-10 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +1,000 | 24.0K | +4% | +$2,480 |
| D | 2025-07-14 | 2025-07-10 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.66 | -1,000 | 23.0K | -4% | -$22.7K |
| D | 2025-07-01 | 2025-06-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 26.2K | +14% | +$8,060 |
| DM | 2025-07-01 | 2025-06-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $20.91 | -3,250 | 23.0K | -12% | -$68.0K |
| D | 2025-06-17 | 2025-06-13 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.55 | -3,000 | 23.0K | -12% | -$67.7K |
| D | 2025-06-17 | 2025-06-13 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,000 | 26.0K | +13% | +$7,440 |
| D | 2025-05-29 | 2025-05-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 26.2K | +14% | +$8,060 |
| D | 2025-05-29 | 2025-05-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $16.18 | -3,250 | 23.0K | -12% | -$52.6K |
| D | 2025-04-30 | 2025-04-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 26.2K | +14% | +$8,060 |
| DM | 2025-04-30 | 2025-04-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $18.69 | -3,250 | 23.0K | -12% | -$60.7K |
| D | 2025-03-31 | 2025-03-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $21.33 | -3,250 | 23.0K | -12% | -$69.3K |
| D | 2025-03-31 | 2025-03-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 26.2K | +14% | +$8,060 |
| D | 2025-03-26 | 2025-03-24 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +1,000 | 24.0K | +4% | +$2,480 |
| D | 2025-03-26 | 2025-03-24 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.50 | -1,000 | 23.0K | -4% | -$22.5K |
| D | 2025-03-06 | 2025-03-04 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +10.0K | 23.0K | +77% | +$24.8K |
| D | 2025-03-03 | 2025-02-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $20.41 | -3,250 | 13.0K | -20% | -$66.3K |
| D | 2025-03-03 | 2025-02-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 16.2K | +25% | +$8,060 |
| D | 2025-02-07 | 2025-02-05 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +1,000 | 14.0K | +8% | +$2,480 |
| D | 2025-02-07 | 2025-02-05 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.52 | -1,000 | 13.0K | -7% | -$22.5K |
| D | 2025-01-29 | 2025-01-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $21.59 | -3,250 | 13.0K | -20% | -$70.2K |
| D | 2025-01-29 | 2025-01-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 16.2K | +25% | +$8,060 |
| DM | 2025-01-07 | 2024-12-13+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +14.0K | 14.0K | New | +$34.7K |
| D | 2025-01-07 | 2025-01-03 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $25.04 | -1,000 | 13.0K | -7% | -$25.0K |
| DM | 2024-12-31 | 2024-12-27+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +4,250 | 900 | New | +$10.5K |
| DM | 2024-12-31 | 2024-12-27+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.23 | -4,250 | 0 | -100% | -$94.5K |
| D | 2024-12-02 | 2024-11-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +5,250 | 5,250 | New | +$13.0K |
| DM | 2024-12-02 | 2024-11-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $24.89 | -5,250 | 0 | -100% | -$130.7K |
| D | 2024-10-30 | 2024-10-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +6,250 | 6,250 | New | +$15.5K |
| DM | 2024-10-30 | 2024-10-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $28.55 | -6,250 | 650 | -91% | -$178.5K |
| D | 2024-10-22 | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +814 | 814 | New | +$2,019 |
| D | 2024-10-22 | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $30.00 | -814 | 0 | -100% | -$24.4K |
| DM | 2024-10-08 | 2024-10-04+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +11.5K | 10.2K | New | +$28.5K |
| DM | 2024-10-08 | 2024-10-04+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $27.51 | -11.5K | 0 | -100% | -$316.0K |
| D | 2024-10-03 | 2024-10-01 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +521 | 521 | New | +$1,292 |
| D | 2024-10-03 | 2024-10-01 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $27.54 | -521 | 0 | -100% | -$14.3K |
| DM | 2024-10-01 | 2024-09-27+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +6,250 | 4,250 | New | +$15.5K |
| DM | 2024-10-01 | 2024-09-27+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $24.61 | -6,250 | 0 | -100% | -$153.8K |
| D | 2024-08-29 | 2024-08-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.54 | -4,250 | 0 | -100% | -$95.8K |
| D | 2024-08-29 | 2024-08-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +4,250 | 4,250 | New | +$10.5K |
| D | 2024-08-02 | 2024-07-31 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +991 | 991 | New | +$2,458 |
| D | 2024-08-02 | 2024-07-31 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $27.53 | -991 | 0 | -100% | -$27.3K |
| DM | 2024-07-31 | 2024-07-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $26.68 | -5,250 | 0 | -100% | -$140.1K |
| D | 2024-07-31 | 2024-07-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +5,250 | 5,250 | New | +$13.0K |
| D | 2024-07-16 | 2024-07-12 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,000 | 3,000 | New | +$7,440 |
| D | 2024-07-16 | 2024-07-12 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $25.07 | -3,000 | 0 | -100% | -$75.2K |
| DM | 2024-07-01 | 2024-06-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.57 | -4,250 | 0 | -100% | -$95.9K |
| D | 2024-07-01 | 2024-06-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +4,250 | 4,250 | New | +$10.5K |
| DM | 2024-05-30 | 2024-05-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $23.18 | -4,250 | 10 | -100% | -$98.5K |
| D | 2024-05-30 | 2024-05-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +4,250 | 4,250 | New | +$10.5K |
| D | 2024-05-07 | 2024-05-03 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.50 | -1,000 | 0 | -100% | -$22.5K |
| D | 2024-05-07 | 2024-05-03 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +1,000 | 1,000 | New | +$2,480 |
| D | 2024-05-01 | 2024-04-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $16.97 | -3,250 | 0 | -100% | -$55.2K |
| D | 2024-05-01 | 2024-04-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 3,250 | New | +$8,060 |
| D | 2024-04-15 | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +14.0K | 14.0K | New | +$34.7K |
| DM | 2024-04-15 | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $24.73 | -14.0K | 0 | -100% | -$346.2K |
| DM | 2024-03-29 | 2024-03-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $18.25 | -3,250 | 182 | -95% | -$59.3K |
| D | 2024-03-29 | 2024-03-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 3,250 | New | +$8,060 |
| D | 2024-02-29 | 2024-02-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $16.97 | -3,250 | 0 | -100% | -$55.2K |
| D | 2024-02-29 | 2024-02-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 3,250 | New | +$8,060 |
| D | 2024-01-31 | 2024-01-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $15.81 | -3,250 | 0 | -100% | -$51.4K |
| D | 2024-01-31 | 2024-01-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 3,250 | New | +$8,060 |
| DM | 2024-01-02 | 2023-12-28+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +11.9K | 9,383 | New | +$29.4K |
| DM | 2024-01-02 | 2023-12-28+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $15.02 | -11.9K | 0 | -100% | -$178.3K |
| DM | 2023-12-27 | 2023-12-22+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $15.06 | -1,130 | 0 | -100% | -$17.0K |
| DM | 2023-12-27 | 2023-12-22+ | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | M - OptEx | $2.48 | +1,130 | 100 | New | +$2,802 |
Purchase Sale Sale after option exercise All abbreviations